Dr. Richardson on Isatuximab Triplet Regimen in Relapsed/Refractory Myeloma

OncLiveTV
04 Jun, 2019 ,

Dr. Richardson discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.